Vim & Vigor, Inc. – Trademark Portfolio
Entity Type: 03
Vim & Vigor, Inc. holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 3 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include CITRICARE, COLLAGENATE, VIM & VIGOR, MOVEMENT ESSENTIALS, and THE PAIN FIX PROTOCOL.
26540 Agoura Rd., Suite 100
Showing of trademarks Trademarks
Trademark Classifications
Vim & Vigor, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Education; providing of training; entertainment; sporting and cultural activities
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Vim & Vigor, Inc. have?
Vim & Vigor, Inc. has 11 U.S. trademarks filed with the USPTO. Of these, 6 registered, 5 abandoned.
What trademark classes does Vim & Vigor, Inc. file in?
Vim & Vigor, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Vim & Vigor, Inc.'s most well-known trademarks?
Vim & Vigor, Inc.'s registered trademark portfolio includes well-known marks such as CITRICARE, COLLAGENATE, VIM & VIGOR, MOVEMENT ESSENTIALS, and THE PAIN FIX PROTOCOL. These are among 6 currently registered trademarks in the portfolio.
What is Vim & Vigor, Inc.'s trademark registration success rate?
Vim & Vigor, Inc. has a 55% trademark registration rate, with 6 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.